Prosensa Priced, Nasdaq: RNA.X
Late-stage biotech developing treatments for Duchenne muscular dystrophy.
Industry: Health Care
First Day Return: +48.1%
RNA.X
Late-stage biotech developing treatments for Duchenne muscular dystrophy.
| IPO Data | |
|---|---|
| IPO Date | 06/27/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $78 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Leiden, Netherlands |
| Founded | 2002 |
| Employees at IPO | 85 |
| Website www.prosensa.com | |
Prosensa (RNA.X) Performance
